A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis

Medical Science Monitor

Volumn 17, Issue 6, 2011, Pages

  de los Angeles Pineda, Maria ^a   Thompson, Sarah Frances ^a   Summers, Kelly ^b,c   de Leon, Faye ^d   Pope, Janet ^c,e   Reid, Gregor ^b,c  

^a WESTERN UNIVERSITY   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Lactobacillus; Probiotics; Randomized controlled trial; Rheumatoid arthritis (RA)

Indexed keywords

AUROTHIOMALATE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79958729747     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881808     Document Type: Article

References (30)

1. Mielants H, De Vos M, Cuvelier C, Veys EM: The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta Clin Belg, 1996; 51: 340-349
2. Tiwana H, Walmsley RS, Wilson C et al: Characterization of the humoral immune response to Klebsiella species in inflammatory bowel disease and ankylosing spondylitis. Br J Rheumatol, 1998; 37: 525-531
3. Hvatum M, Kanerud L, Hallgren R, Brandtzaeg P: The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. Gut, 2006; 55: 1240-1247
4. Danning CL, Boumpas DT: Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanisms of action. Clin Exp Rheumatol, 1998; 16: 595-604
5. Müller H, de Toledo FW, Resch KL: Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. Scand J Rheumatol, 2001; 30: 1-10
6. Peltonen R, Nenonen M, Helve T et al: Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol, 1997; 36: 64-68
7. Food and Agriculture Organization of the UN and WHO: Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. 2001, Oct 1-4; Cordova, Argentina; Food and Nutrition Paper, issue 85. Available from: ftp://ftp.fao.org/docrep/fao/009/a0512e/A0512E00.pdf
8. Strowski MZ, Wiedenmann B: Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases. Gut, 2009; 58: 1044-1045
9. Brandtzaeg P: Induction of secretory immunity and memory at mucosal surfaces. Vaccine, 2007; 25: 5467-5484
10. Kim SO, Sheikh HI, Ha SD et al: G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages. Cell Microbiol, 2006; 8: 1958-1971
11. Kano H, Kaneko T, Kaminogawa S: Oral intake of Lactobacillus delbrueckii subsp. Bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Foo Prot, 2002: 65(1): 153-160
12. Rovensky J, Svik K, Matha V et al: Combination treatment of rat adjuvant- induced arthritis with methotrexate, probiotic bacteria Enterococcus faecium, and selenium. Ann NY Acad Sci, 2005; 1051: 570-581
13. ®). Folia Microbiol, 2009; 54: 359-363
14. Stebbings S, Munro K, Simon MA et al: Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology (Oxford), 2002; 41: 1395-1401
15. Baharav E, Mor F, Halpern M, Weinberger A: Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr, 2004; 134: 1964-1969
16. Hatakka K, Martio J, Korpela M et al: Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis - a pilot study. Scand J Rheumatol, 2003; 32: 211-215
17. Christensen HR, Frøkiaer H, Pestka JJ: Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol, 2002; 168: 171-178
18. Wolfe F, Cathey MA: The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol, 1994; 18: 1298-1306
19. McInnes IB, Schett G: Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol, 2007; 7(6): 429-442
20. Klareskog L, Catrina AI, Paget S: Rheumatoid arthritis. Lancet, 2009; 373(9664): 659-672
21. De Stefano R, Frati E, Nargi F et al: Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol, 2010; 29(5): 517-524
22. Koch AE: Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum, 2005; 52(3): 710-721
23. Iwamoto T, Okamoto H, Toyama Y, Momohara S: Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J, 2008; 275(18): 4448-4455
24. Gu L, Tseng S, Horner RM et al: Control of TH2polarization by the chemokine monocyte chemoattractant protein-1. Nature, 2000; 404(6776): 407-411
25. Daly C, Rollins BJ: Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation, 2003; 10(3-4): 247-257
26. Dawson J, Miltz W, Mir AK, Wiessner C: Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets, 2003; 7(1): 35-48
27. McDougall J, Bruce B, Spiller G et al: Effects of a very low-fat, vegan diet in subjects with rheumatoid arthritis. J Altern Complement Med, 2002; 8(1): 71-75
28. Anukam K, Osazuwa E, Ahonkhai I et al: Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect, 2006; 8: 1450-1454
29. Martinez RC, Franceschini SA, Patta MC et al: Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol, 2009; 48: 269-274
30. Martinez RC, Franceschini SA, Patta MC et al: Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol, 2009; 55: 133-138